Research News

A Researcher’s Breakthrough Moment

Friday, 17 February 2017 09:51

The Kenneth Rainin Foundation posted a video about a breakthrough moment for Dr. Gwendalyn Randolph. This pioneering researcher was recently awarded a Synergy Award from the Foundation. Her cutting-edge instincts led to a novel technique and the ability to peer more deeply into the workings of Crohn's disease.

Rainin Foundation awards $750,000 for IBD research

Friday, 17 February 2017 09:31

On 10 Feb 2017, the Kenneth Rainin Foundation announced that it has awarded $750,000 for Inflammatory Bowel Disease (IBD) research through its Synergy Award program. The Rainin Foundation funds scientific projects that have the potential to yield transformative discoveries and major insights into predicting and preventing IBD. Further details of the projects and awards can be found in their blog. The Synergy Awards are intended to foster collaboration. The Synergy Award programme is one of three grant programmes the Rainin Foundation offers for IBD-related research.

TRITON grant announcement

Wednesday, 15 February 2017 17:21

Professor Spiller and a team of experts from the Neurogastroenterology & Motility Section of the British Society of Gastroenterology who are based in 12 major research centres in the UK have been awarded a £2.1M grant from the National Institute of Health Research Efficacy and Mechanism Evaluation (NIHR EME) Programme to perform a clinical trial entitled "Treatment of IBS with diarrhoea with Titrated Ondansetron (TRITON)”. The trial will be coordinated from the Leeds Clinical Trials Research Unit and the mechanistic studies will involve specialist centres in Leeds, University College London and Barts and the London Hospital. Recruitment is expected to start in autumn 2017.

The trial offers a great opportunity for two specialist registrars to obtain a higher degree in the rapidly expanding field of neurogastroenterology. The trial will include studies of how ondansetron affects bowel motility and sensitivity. Understanding how ondansetron works will improve our ability to predict who will respond and will inform the development of new treatments for this common and distressing condition. One registrar will be based at QMC, Nottingham and the other at QMUL, London; both are expected to start their fully supported OOP work in September 2017. The posts will be advertised soon with full information on how to apply.

Detection of UGI cancer with a breath test

Wednesday, 15 February 2017 10:39

Researchers at the 2017 European Cancer Conference have reported that work funded by the NIHR has the potential to achieve earlier diagnosis of oesophageal and stomach cancer. They have developed a breath test to detect the levels of five chemicals previously shown to differ between patients with stomach or oesophageal cancer and patients with upper gastrointestinal symptoms without cancer. The new research aimed to test whether this ‘chemical signature’ that seemed to typify cancer could be the basis of a diagnostic test. See the Conference news report and the NIHR news report for more details.

Page 9 of 39